Susceptibility to quinupristin/dalfopristin and other antibiotics of vancomycin-resistant enterococci from the UK, 1997 to mid-1999

被引:14
作者
Johnson, AP [1 ]
Warner, M [1 ]
Hallas, G [1 ]
Livermore, DM [1 ]
机构
[1] Cent Publ Hlth Lab, Antibiot Resistance Monitoring & Reference Lab, London NW9 5HT, England
关键词
D O I
10.1093/jac/46.1.125
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Susceptibility to quinupristin/dalfopristin and other antibiotics was studied far clinical isolates of vancomycin-resistant enterococci (VRE) referred by UK hospitals between January 1997 and June 1999. Single isolates of VRE from 858 patients in 136 hospitals were received, of which 76% were Enterococcus faecium and 21% were Enterococcus faecalis, the remainder comprising minor species. Most isolates were multi-resistant. After allowing for the effect of blood, which raised the MICs of quinupristin/dalfopristin four-fold, 98.3% of E. faecalis isolates and all the Enterococcus avium, Enterococcus casseliflavus and Enterococcus gallinarum appeared resistant to quinupristin/dalfopristin, whereas 98.8% of the E. faecium isolates and the single Enterococcus raffinosus isolate were susceptible.
引用
收藏
页码:125 / 128
页数:4
相关论文
共 10 条
[1]   Study to assess the reliability of a disc diffusion method for determining the sensitivity of Gram-positive pathogens to dalfopristin/quinupristin [J].
Andrews, JM ;
Ashby, JP ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :141-143
[2]   DETECTION OF GLYCOPEPTIDE RESISTANCE GENOTYPES AND IDENTIFICATION TO THE SPECIES LEVEL OF CLINICALLY RELEVANT ENTEROCOCCI BY PCR [J].
DUTKAMALEN, S ;
EVERS, S ;
COURVALIN, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1995, 33 (01) :24-27
[3]   Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods [J].
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 26 (02) :99-102
[4]   Antimicrobial activity of quinupristin-dalfopristin (RP 59500, synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the united states and Canada [J].
Jones, RN ;
Ballow, CH ;
Biedenbach, DJ ;
Deinhart, JA ;
Schentag, JJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (03) :437-451
[5]   Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results [J].
King, A ;
May, J ;
Phillips, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :711-719
[6]  
PHILLIPS I, 1991, J ANTIMICROBIAL C SD, V27, P5
[7]  
*PUBL HLTH LAB SER, 1996, COMMUN DIS REP CDR W, V6, P267
[8]  
Woodford N, 1997, LANCET, V350, P738, DOI 10.1016/S0140-6736(05)63544-1
[9]   CURRENT PERSPECTIVES ON GLYCOPEPTIDE RESISTANCE [J].
WOODFORD, N ;
JOHNSON, AP ;
MORRISON, D ;
SPELLER, DCE .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :585-&
[10]  
*WORK PART SENS TE, 1998, NEWSLETTER BRIT SUM